Targeting PD-1/PD-L1 in lung cancer: current perspectives

Código QR

Targeting PD-1/PD-L1 in lung cancer: current perspectives

María González-Cao,1 Niki Karachaliou,1 Santiago Viteri,1 Daniela Morales-Espinosa,1 Cristina Teixidó,2 Jesús Sánchez Ruiz,3 Miquel Ángel Molina-Vila,2 Mariacarmela Santarpia,4 Rafael Rosell1,2,5,61Translational Cancer Research Unit,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	González-Cao M, Karachaliou N, Viteri S, Morales-Espinosa D, Teixidó C, Sánchez Ruiz J, Molina-Vila MÁ, Santarpia M, Rosell R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/53cb1147aa7d460ab1939a5683d7eba4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Functionalization of immunostimulating complexes (ISCOMs) with lipid vinyl sulfones and their application in immunological techniques and therapy
por: Cruz-Bustos T, et al.
Publicado: (2012)

Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors
por: Sarah J. Dart, et al.
Publicado: (2021)

Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer
por: Nitin Roper, et al.
Publicado: (2021)

Role of the transient receptor potential vanilloid 1 in inflammation and sepsis
por: Devesa I, et al.
Publicado: (2011)

Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer
por: A. N. Niemeijer, et al.
Publicado: (2018)

Correlation Between Peripheral Blood Biomarkers and Efficacy of PD-1/PD-L1 Inhibitors Treatment on Lung Cancer
por: KE Ping, et al.
Publicado: (2021)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea M, et al.
Publicado: (2021)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
por: Hyun Tae Lee, et al.
Publicado: (2017)

Congenital anophthalmia and microphthalmia: epidemiology and orbitofacial rehabilitation
por: Llorente-Gonz&aacute;lez S, et al.
Publicado: (2011)

Dl-3-N-Butylphthalide Presents Anti-Cancer Activity in Lung Cancer by Targeting PD-1/PD-L1 Signaling
por: Jiang Q, et al.
Publicado: (2021)

Endocrine Disorders Induced by PD-1/PD-L1 Inhibitor and Related Treatment
por: LAI Yanliang, et al.
Publicado: (2021)

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
por: Zhitao Li, et al.
Publicado: (2021)

Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
por: Utpal Kumar, et al.
Publicado: (2021)

Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer
por: Yoshihisa Shimada, et al.
Publicado: (2021)

Evolution of visual performance in 70 eyes implanted with the Tecnis&reg; ZMB00 multifocal intraocular lens
por: Palomino Bautista C, et al.
Publicado: (2012)

Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer
por: Clemens Hinterleitner, et al.
Publicado: (2021)

Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
por: Min Yu, et al.
Publicado: (2021)

Depletion of PD-1 or PD-L1 did not affect the mortality of mice infected with Mycobacterium avium
por: Masayuki Nakajima, et al.
Publicado: (2021)

A review of the potential therapeutic role of statins in the treatment of Alzheimer&rsquo;s disease: current research and opinion
por: Mitchell AJ, et al.
Publicado: (2013)

Correction: Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
Publicado: (2021)

Efficacy of PD‐1/PD‐L1 inhibitors in patients with non‐small cell lung cancer and brain metastases: A real‐world retrospective study in China
por: Jiamin Sheng, et al.
Publicado: (2021)

PD-1 pathway regulates ILC2 metabolism and PD-1 agonist treatment ameliorates airway hyperreactivity
por: Doumet Georges Helou, et al.
Publicado: (2020)

Stomach cancer. Clinical significance of the expression of key components of PD-1/PD-L1 immune checkpoint
por: Olga V. Kovaleva, et al.
Publicado: (2021)

Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
por: Miao Wang, et al.
Publicado: (2021)

Retinoschisis and macular detachment associated with acquired enlarged optic disc cup
por: Moreno-L&oacute;pez M, et al.
Publicado: (2012)

The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia
por: Laura Jimbu, et al.
Publicado: (2021)

Disease-modifying therapies in relapsing&ndash;remitting multiple sclerosis
por: Fabricio Gonz&aacute;lez-Andrade, et al.
Publicado: (2010)

Effectiveness of the Mediterranean diet in the elderly
por: Blanca Roman, et al.
Publicado: (2008)

The Prognostic Significance of PD1 and PDL1 Gene Expression in Lung Cancer: A Meta-Analysis
por: Chih-Hao Chang, et al.
Publicado: (2021)

Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade
por: Guido Kroemer, et al.
Publicado: (2021)

Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis
por: Yixi Zhang, et al.
Publicado: (2021)

Sulforaphane enhances the antitumor response of chimeric antigen receptor T cells by regulating PD-1/PD-L1 pathway
por: Chunyi Shen, et al.
Publicado: (2021)

Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
por: Yang Hu, et al.
Publicado: (2021)

Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion
por: David H. Peng, et al.
Publicado: (2020)

Different Induction of PD-L1 (CD274) and PD-1 (CD279) Expression in THP-1-Differentiated Types 1 and 2 Macrophages
por: Lai CY, et al.
Publicado: (2021)

Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
por: Peiyi Xie, et al.
Publicado: (2021)

Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors.
por: Keller J Toral, et al.
Publicado: (2021)

Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer
por: Grégoire de Streel, et al.
Publicado: (2020)

Safety of thoracic radiotherapy after PD‐(L)1 inhibitor treatment in patients with lung cancer
por: Yu Chen, et al.
Publicado: (2021)

Pigment dispersion syndrome associated with intraocular lens implantation: a new surgical technique
por: M Isabel Canut Jordana, et al.
Publicado: (2010)